Explore terminated, suspended, and withdrawn clinical trials

The study ended early after interim analysis.

Other - Extend the observation period for current patients

Placed on voluntary hold to new recruitment pending modification to combination monoclonal antibody treatment.

Sponsor decision based on limited clinical benefit observed in both Multiple Myeloma and Non-Hodgkin Lymphoma cohorts

The study was terminated due to low accrual and insufficient efficacy seen in first few participants treated.

slow accrual

Lack of clinical benefit

the pandemic of COVID-19 was over.

Change of protocol title

Staffing disruptions leading to incomplete study enrollment prior to PI departure.

The study remains on hold due to a funding issue after it's been lifted by the FDA.

Per sponsor letter, due to a business decision based on reprioritization of their internal XmAb20717 programs, Xencor has determined that ECR003 activities must halt and no additional subjects may be enrolled

Administrative hold pending non-safety related changes to the study design.

Revisions to eligibility/design being made prior to enrollment of first participants.

The interim analysis results met protocol and SAP predetermined criteria for stopping early due to futility or efficacy.

Study on hold pending possible updates with the team.

Withdrawn due to duplicate registration

Stopped for futility - no safety issues.

PI Request

End of Initial Phase of Multi-phase protocol

Accrual Goal Met

Sponsor decision. Not related to safety concern.

Accrual and drug manufacturing and supply were discontinued in 2025.

The trial has been stopped pending FDA approval of modifications to the trial protocol.

Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial.

After reviewing all available data from Part 1 of the trial, the Sponsor has decided not to proceed to Part 2 (randomized Phase 2) of the trial due to lack of efficacy

Following interim analysis for futility

Study tracer is currently unavailable

The intervention was deemed futile the intervention group, as TDM was not needed in patients with a 12mg/kg dose. In consultation with the METC and biostatistics it was decided to terminate the study early.

Lack of eligible patients due to lower number of Covid-19 cases in all involved sites.

Terminated early due to insufficient accrual to meet prespecified statistical analysis requirements.

PI opted to close study due to poor accrual.

The trial was terminated on the independent DSMB's recommendation after an interim analysis showed no evidence of benefit and a numerically higher incidence of postoperative delirium in the droperidol group, raising a potential safety concern.

Lack of funding

Corporate decision

funding

The trial stopped early due to meeting interim analysis early stopping rules. Active participants at the time of the interim analyses results did complete their remaining study visits. No new participants were enrolled.

slow accruals

No longer relevant to field

Sponsor Decision

Terminated due to strategic decision

—

The study was terminated due to lack of enrollment resulting from a change in the standard of care for the first-line treatment of patients with cholangiocarcinoma. There were no safety concerns that contributed to this decision.

Per sponsor request

The study stopped early, before enrolling its first participant

Sponsor's decision

Sponsor Decision

Sponsor Decision

Enrollment challenges.

Pfizer has made an internal business decision to not continue this study. This decision was not due to safety concerns or clinical effect reasons or requests from any regulatory authorities.